TNF and juvenile idiopathic arthritis: As significant biologic therapeutics, tumor necrosis factor-alpha (TNF-α) inhibitors have achieved groundbreaking progress in treating pediatric chronic inflammatory diseases, including inflammatory bowel disease (IBD) and juvenile idiopathic arthritis (JIA) [1].